Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131014 · ClinicalTrials.gov registry record
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
A clinical trial of Non-Hodgkin's Lymphoma and Hodgkin's Disease, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT00131014: Recruiting study of Non-Hodgkin's Lymphoma and Hodgkin's Disease, sponsored by Dana-Farber Cancer Institute.
NCT00131014 is a study of Non-Hodgkin's Lymphoma and Hodgkin's Disease that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,500 participants, above the 198-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (658% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00131014, a study of Non-Hodgkin's Lymphoma and Hodgkin's Disease, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.
Primary Outcome
Genetic factors that contribute to the development of lymphomas and CLL
Conditions Studied
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2004-08-09 |
| Est. Completion | 2033-01 |
What NCT00131014 shows while recruiting
NCT00131014 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 198-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (658% higher).
The record links to 4 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT00131014 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00131014 about?
NCT00131014 is a clinical study titled "Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies". The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers...
What is the current status of trial NCT00131014?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2004-08-09. Estimated completion is 2033-01.
What conditions does trial NCT00131014 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Hodgkin's Disease, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic.
Who is sponsoring clinical trial NCT00131014?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00131014 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00131014's enrollment target sits among peer trials
1,500 4th of 63 higher than 60 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
RECRUITING
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI